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Abstract: The implementation of Raman and surface enhanced Raman spectroscopy (SERS) for the 
detection of disease has increased in recent years. The reasons for their increased implementation 
have often been attributed to their well-known advantages, including the production of narrow 
spectral bands, which are characteristic of the molecular components present, their non-destructive 
method of analysis and the sensitivity and specificity which they can confer. This review analyses a 
range of diseases which can be detected by Raman or SERS, particularly those in vitro, ex vivo and in 
vivo. The sophistication of the investigated systems varied widely but the suitability of Raman and 
SERS for medical diagnostics and future implementation in a clinical environment is clearly 
demonstrated.  
 
Highlights:  
x A range of diseases can be detected by Raman and SERS in vitro, ex vivo and in vivo 
x In vivo multiplexed detection of cancer was achieved 
x SERS is also a key step in disease treatment 
x Studies must be further extended to a physiologically relevant medium and in vivo  
x The potential exists for the application of the techniques in a clinical setting 
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1. Introduction 
When the pioneers of Raman spectroscopy initially conceived the technique in 1923 [1] and latterly 
demonstrated it in 1928 [2] it is unlikely that they had any inclination of the future impact or bio-
diagnostic applications. [3-5] In particular, the use of Raman spectroscopy for in vitro, ex vivo and in 
vivo disease detection has proliferated over the last decade. This is unsurprising when considering 
the non-invasive nature of the technique and the provision of molecularly specific spectra which 
allow for the identification of disease targets. [6] However, the obvious disadvantage with its 
implementation is that it can be quite insubstantial, especially considering that approximately only 
one in every million photons are Raman scattered. [6] 
 
This weak effect was negated by successive developments of the original technique most notably  
surface enhanced Raman spectroscopy (SERS) [7-9] and surface enhanced resonance Raman 
spectroscopy (SERRS), [10] where signal enhancements of the order of 10
10 
[8, 9, 11] and 10
14
 [10] 
were observed respectively. The incorporation of a roughened metal surface (metal electrodes, 
coatings, surfaces and nanostructures)[11] is essential for manipulation of the SERS enhancement, 
which is widely believed within the community to arise through a combined electromagnetic and 
chemical effect. [6, 11, 12] SERRS, whilst manipulating the enhancement conferred by a roughened 
metallic scaffold, additionally exploits excitation with a laser line that corresponds to an electronic 
transition of the interrogated analyte to further augment the enhancement effect. [10] 
 
The introduction of nanostructures can render these techniques invasive however; this can be offset 
by the conferred enhancement. As with the original method, the employment of SERS for disease 
detection in vitro, ex vivo and in vivo has increased exponentially, again a direct consequence of the 
molecularly definitive spectra which allow for confident identification of disease biomarkers. 
However, as clinical medicine strives towards a personalised approach, there is further need to 
increase the sensitivity and specificity by which diseases are detected and the simultaneous 
requirements of comprehensive characterisation and detection of multiple pathosis. [13] SERS is 
ideally suited to fulfil these requirements since the observed enhancement can satisfy the sensitivity 
criteria whilst functionalisation with specific targeting moieties allows for disease recognition with a 
high degree of specificity. The sharp bands produced within a SERS spectrum lend the technique to 
multiplexed detection satisfying the demand to diagnose multiple aspects of a single disease or a 
myriad of disorders. [13] 
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This review will examine the application of SERS for disease detection. A range of formats will be 
discussed, including in vitro analysis of simple matrices to more sophisticated analysis in vivo but 
with the predominant focus on mapping/imaging applications. The review will additionally highlight 
the progression of the technique from a simple lab based analytical method to a contender for the 
interrogation and discernment of clinical samples.  The advancement of SERS as a diagnostic imaging 
method is developing at a ferocious pace and if maintained at this level, there is huge potential to 
revolutionise the ability to detect, treat and manage disease.  
 
2. Raman Spectroscopy and Disease Detection 
While this review will predominantly concentrate on SERS it is worth highlighting the parallel 
advancements occurring with Raman spectroscopy.  The obvious advantage of Raman spectroscopy 
over SERS is that it is non-invasive so there is no requirement for the introduction of nanostructures 
to observe a response. In terms of in vitro, ex vivo and in vivo analysis, this is particularly beneficial 
since minimal sample preparation is involved, toxicity trials are not required as adulterants have not 
been introduced and more importantly for in vivo studies there is no need to consider the 
distribution and localisation of nano-scaffolds for effective analysis. However, consideration must be 
given to the employed laser power, acquisition time and sample format to prohibit sample 
degradation and auto-fluorescence. 
 
2.1 Raman Spectroscopy and In vitro Cell Analysis 
The interrogation of single cells and cell populations may not have the same allure and glamour of in 
vivo studies but, in terms of indicators of disease, they can be equally important. The architecture of 
the cell can be altered considerably during processes such as differentiation [14], mitosis and 
apoptosis [15]. Uncontrolled division and cell death can be indicative of pathosis, including tumour 
growth, inflammation, HIV infection and neurodegeneration diseases ƐƵĐŚ ĂƐ WĂƌŬŝŶƐŽŶ ?Ɛ ĂŶĚ
ůǌŚĞŝŵĞƌ ?Ɛ. [16] Monitoring the cell composition and architecture permits a viable method for the 
detection of disease and, with the advent of 3D Raman imaging, the resolution of cell organelles may 
be more representative of the disease led changes that can occur intracellularly. [17, 18] Cell health 
can also be directly monitored via Raman spectroscopy and it is possible to distinguish between live 
and dead cells, [19] and cells that are stressed, [20] conditions which can arise as a result of infection 
or disease. Cells can also be readily distinguished on the basis of their phenotypic differences and 
this has been used to discriminate between bone [21] and lung cells, [22] and more importantly in 
terms of disease diagnosis between cancerous and non-cancerous cells. [23, 24] This was not 
completed with a clinical sample but the authors highlighted the desire to extend analysis into urine. 
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[23] In a clinical setting, this has the potential to provide cancer diagnosis non-invasively via an 
excretory product. 
 
2.2 Raman Spectroscopy and Ex vivo/In vivo Applications for the Detection of Disease 
As a diagnostic tool, Raman spectroscopy is forging ahead in the cancer field providing a method by 
which to detect breast [25-27], skin [28, 29], prostate [30-32], bladder [33-35], cervical [36-38], 
colorectal [39, 40] and oesophageal cancer [41, 42]. With bladder, [34, 35] cervical, [37, 38] 
colorectal [43] and oesophageal cancer [42] all being detected in vivo. The incidence of breast cancer 
in the UK accounts for the greatest proportion of all cancer diagnosis and like all forms of the disease 
there is demand for sensitive, selective and non-invasive detection. [44] A subsequent adaptation of 
the original Raman technique led to the development of spatially offset Raman spectroscopy (SORS) 
which has a demonstrated ability to differentiate between calcifications associated with cancerous 
and non-cancerous tissues and at a reported depth of ~ 8.7 mm. [26] The authors reported that this 
could be used to complement the current clinical method of detection, mammography, whilst 
simultaneously demonstrating the potential to minimise the number of invasive biopsies. [26] 
Successive developments and the implementation of a transmission Raman setup increased the 
thickness of tissue through which cancerous and non-cancerous samples could be differentiated. 
[27] The depth of detection was increased to 27 mm with anything above 20 mm being classified as 
clinically significant for in vivo detection, further highlighting the applicability and relevance of 
implementing the technique in a clinical environment. [27] A proof of concept study also 
investigated the possibility of detecting brain tumours in vivo in mice models. [45] The authors 
reported that the tumours could be located with an accuracy of approximately 250 µm and while 
principally a demonstration of what could be achieved, the authors emphasised the possibility of 
using Raman spectroscopy for brain analysis and tumour detection in a live subject. [45] 
 
Raman spectroscopy is not limited to the detection of cancer and research has postulated that the 
method could be used for the characterisation and monitoring of atherosclerotic plaques. [46] In the 
UK alone coronary heart disease and the conditions which stem from it cost an estimated £19 billion. 
[47] This is clearly an extensive and significant problem and Raman was found to be a suitable 
method by which plaque deposits could be distinguished and their size determined. [46] The effects 
of statin drug treatment were also tracked, and in mice that were provided a cholesterol rich diet, 
the statins successfully minimised plaque formation. [46] Whilst this remains a proof-of-principal 
study there is potential for extension to studies in man and although not demonstrated remote 
sensing could be achieved by coupling via a fibre optic probe. [46]  
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Similarly, Raman spectroscopy has been implemented to monitor organ rejection in patients 
following transplant procedures. [48, 49] While not directly involving the detection of disease, it is 
possible that the processes which led to transplant were the result of disease, for example, coronary 
heart or chronic kidney disease. This demonstrates the application of Raman for monitoring 
subsequent disease effects. In the particular instances of heart and kidney transplant the 
confirmation of rejection requires an invasive biopsy procedure and the observation of an elevated 
serum creatinine level, respectively. [48] However, the rejection of heart tissues can be 
characterised by serotonin biomarkers, which can be detected using Raman, presenting a viable non-
invasive alternative to biopsy. [49] While the methods for monitoring kidney rejection do not require 
the same invasive procedures, by the time detection of serum creatinine is confirmed significant 
deterioration of the organ can have occurred. [48] Raman spectroscopy was employed as a method 
to differentiate between T-cells which were produced in response to different stimuli (i.e. in 
response to rejection and under normal circumstances). [48] These were selected as biomarkers for 
monitoring the rejection response since the process is primarily characterised by T-cells. The 
technique was found to be suitable for differentiating between normal cells and those which are 
characteristic of a rejection response. [48] It should be noted that the T-cells were not directly 
obtained from a patient undergoing rejection but rather the cells were artificially modelled to be 
representative. Raman spectroscopy therefore represents a viable alternative by which rejection 
could be monitored. 
 
This is in no way an exhaustive review of the methods by which Raman spectroscopy can be 
employed to detect disease or monitor health, however, it does emphasise the vast array of 
medically related applications. For further discussion regarding the employment and advancements 
of Raman spectroscopy in medicine, readers are encouraged to review literature from the Stone [44] 
and Goodacre groups [50, 51]. However, it is clear that with instrumental improvements and careful 
consideration of the employed laser power and acquisition time, vast amounts of information can be 
yielded by Raman spectroscopy. Central to all of these applications is the employment of 
chemometric methods. Raman spectra are often similar in appearance and discerning any 
differences by eye are difficult, but by implementing chemometric analysis subtle differences can be 
extracted and conclusions drawn with statistical significance. However, in order to make the leap 
from bench to body, further analysis must be completed in physiologically representative media, 
clinical samples and in vivo. [52] While diagnostic information can be extracted using chemometrics 
clinicians require simple yes/no answers to dispense a diagnosis or prognosis. Therefore, any 
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transition to a clinical environment will require coupling of the data collection and analysis so that 
single definitive answers can be provided.  
 
3. Surface enhanced Raman Spectroscopy (SERS) 
The advantages of SERS over conventional Raman were briefly discussed in the introduction but are 
worth re-iterating since these benefits in conjunction with the shortcomings of Raman are 
responsible for the proliferation of the technique. Although, non-invasivity is a key attraction of 
Raman spectroscopy, the overall outcome is that the technique is reliant on spectral signatures from 
the intrinsic components of the interrogated system, which in biological matrices tend to be weak, 
inefficient scatterers and spectrally similar, [53] such that subtle differences must be discerned by 
the incorporation of chemometric methods. SERS unlike Raman is not reliant on native 
chromophores and a vast array of efficient scattering molecules, [54-59] with large Raman cross 
sections, can be conjugated to metallic scaffolds for the provision of distinct, optically strong, 
spectral signatures. By capitalising on this conferred enhancement, through the implementation of a 
metal surface and superior reporting moieties, the measured spectral intensities can be significantly 
enhanced. [8, 9, 11] The key advantages of this enhancement are that a reduced laser power and 
acquisition time can be incorporated for the analysis of fragile samples with minimal loss of the 
spectral sensitivity whereas with conventional Raman some compromise must be made between the 
laser power and measurement time to obtain sufficiently distinct spectra without incurring sample 
damage. The sharp molecularly specific spectra produced by SERS also promote the technique for 
use in multiplexed scenarios including multiple disease detection and in many instances differences 
can be determined by eye without the need for the incorporation of chemometric methods.[13] 
Conventional Raman is unlikely to be employed in such a manner since the spectral differences 
between healthy and diseased samples are extremely subtle, let alone between multiple diseases in 
a single sample, and generally require the implementation of statistical methods for their 
differentiation. [53] 
 
As discussed above exploitation of the SERS effect requires the incorporation of a roughened metal 
surface. [6, 11] The forms which this can take are vast and can include metal electrodes, [10] 
coatings, surfaces [60, 61] and nanostructures. [62, 63] In vitro examples have employed 
unfunctionalised nanoparticles for simple sensing applications, for example, monitoring enzyme 
activity [62] or the determination of intracellular components. [64] To actively image and/or target 
and detect disease in vitro, ex vivo and in vivo the sophistication of the implemented systems varies. 
Ranging from metallic nanoparticles labelled with reporter molecules [65-69] to more complicated 
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systems with mixed reporter monolayers [70], dually functionalised systems consisting of reporter 
molecules and membrane penetrating or targeting antibodies [71-73], peptides [65, 74, 75] or 
oligomers. To minimise or prohibit degradation from the surrounding environment nanostructures 
can be afforded a certain degree of stability by silica [13, 76] or polymer encapsulation. [71, 77, 78] 
The incorporation of polyethylene glycol (PEG) again offers protection from the chemical and 
physical environment, minimisation of non-specific binding [79] and, depending on the terminal 
functionality, PEG is readily amenable for bioconjugation to a range of targeting ligands. [80] 
 
3.1 SERS and In vitro Applications for the Detection of Disease  
SERS based nanotags have been used with a variety of different sample formats for the in vitro 
detection of disease. In some of the earliest examples, functionalised nanoparticles and nanotags 
were not employed for the detection of disease. Instead metallic surfaces were used to exploit the 
SERS effect. In one such system used for the detection of glucose, spheres were coated in a layer of 
silver for the provision of the SERS enhancement and they were subsequently functionalised with 
both decanethiol and mercaptohexanol. [60] Dual functionalisation with molecules of varying chain 
length results in hole formation between the different chains actively providing a region into which 
the glucose molecules can enter and the response can be measured via SERS. [60] With the 
implementation of the system it was possible to quantitatively detect glucose and the majority of 
the measurements were detected within levels which were considered to be medically relevant. [60] 
The authors also reported that the system worked effectively even when interfering analytes were 
present. [60] Detecting glucose in real-time is of huge importance for diabetes sufferers who 
currently check their levels via pin prick blood tests. With this method of monitoring huge variations 
in glucose levels are often missed and in order to improve disease management, there is a real need 
for accurate continuous monitors. [60] Later work by the same group has strived to further develop 
this method for in vivo sensing. [81-83] In the initial stages the sensors (as described above) were 
implanted into animal models and the glucose levels were successfully measured via SERS and 
surface enhanced spatially offset Raman spectroscopy (SESORS) respectively. [81-83]. (SESORS shall 
be discussed further in section 3.3). In the most recent developments, the same sensor has been 
investigated via animal implementation. [83] The device was found to actively work over 17 days and 
more importantly the authors reported that between days 6 and 17, the glucose levels measured 
were found to lie within the clinically relevant levels. [83] This elegant and sophisticated example is a 
significant step forward in the development of a method by which diabetes sufferers could monitor 
and control their condition more accurately. [83] A similar format was also used to monitor lactate 
quantitatively. [61] Variations in lactate levels can be indicative of trauma in a number of medical 
   8 
 
conditions and as with glucose monitoring the ability to measure lactate in real time would further 
improve the clinical care offered to patients suffering from a range of conditions. [61] 
 
In other examples, the SERS enhancement was achieved using metallic nanoparticles. Using this 
format and a nanofluidic device Chou et al. ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĞĚĞƚĞĐƚŝŽŶŽĨƚŚĞɴ-amyloid peptide, 
which is a key component in plaques in sufferers of Alzheimer disease. [63] ɴ-amyloid detection was 
achieved by concentrating the nanoparticles and target molecules within the device, irradiating with 
a laser and monitoring the SERS signal. [63] To demonstrate the sensitivity of the detection system 
the author ?s added additional proteins of similar and different conformations. Analysis of the SERS 
signals found that it was possible to discriminate between the different protein forms, [63] in 
particular, ɲ-helices could be discrimŝŶĂƚĞĚĨƌŽŵɴ-sheets anĚďĞƚǁĞĞŶƚŚĞĚŝĨĨĞƌĞŶƚɴ-sheet forms 
discrimination was also possible. [63] Having a method by which to characterise the disease process 
is hugely beneficial and it could be used as a method to monitor disease development. [63] 
 
Unfunctionalised nanoparticles have also been used to monitor enzyme activity intracellularly. [62] 
This is relevant in terms of disease detection since some notable diseases, including cystic fibrosis, 
WĂƌŬŝŶƐŽŶ ?ƐĂŶĚůǌŚĞŝŵĞƌ ?ƐĂƌĞĂůůĐŚĂƌĂĐƚĞƌŝƐĞĚďǇƐŽŵĞĨŽƌŵŽĨĂďŶŽƌŵĂůĞŶǌǇŵĞĂĐƚŝǀŝƚǇ ?[62] In 
the study Au nanoparticles were incorporated by cell populations alongside the colourless substrate 
X-Gal, where upon internalisation it was enzymatically transformed by ɴ-galactosidase enzymes to 
 ? ? ? ?-dibromo- ? ? ? ?-dichloroindigo. This transformation was characterised by the appearance of a 
peak in the SERS spectra at 598 cm
-1
 and a blue colour which was indicative of the turnover of the 
substrate by the enzyme (Figure 1). [62] The conversion was specific to the enzyme as confirmed 
when known enzyme inhibitors were introduced (Figure 1) and the corresponding reduction in the 
measured SERS signal. [62] High resolution analysis of single cells and cell populations suggested that 
enzyme action was localised in specific cellular compartments which were proposed to be 
endosomes. [62] The authors expressed a desire to quantify enzyme levels within these 
compartments, particularly in response to different disease stimuli and states. It is hoped that such 
knowledge will facilitate the development of suitable treatments. [62] 
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Figure 1: Intracellular conversion of X-Gal to the blue coloured product  ? ? ? ?-dibromo- ? ? ? ?-dichloro indigo by 
ƚŚĞĞŶǌǇŵĞɴ-galactosidase  ?  )ǁŚŝƚĞ ůŝŐŚƚĂŶĚ ĨĂůƐĞĐŽůŽƵƌ ŝŵĂŐĞďĂƐĞĚŽŶ ƚŚĞ  ? ? ? ?-dibromo- ? ? ? ?-dichloro 
indigo peak at 598 cm
-1
, B) corresponding spectra from the highlighted areas and the associated false colour 
LUT bar and C) the effect of an enzyme inhibitor on the measured SERS signals. [62] Modified and reproduced 
by permission of the RSC. 
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More recently systems for disease detection have looked at functionalised nanotags. [84-86] In one 
immunoassay, the detection of the carcinoembryonic antigen (CEA), a marker frequently used for 
the detection of lung cancer, was achieved using a combination of hollow gold nanospheres (HGNs) 
and magnetic beads. [86] Porter et al. also implemented an immunoassay format for the detection 
of the pancreatic cancer marker, MUC4. [84] This marker is suitable for detecting cancer since it 
appears to be absent in healthy and pancreatitis-suffering populations. [84] Detection was achieved 
using SERS via gold nanoparticles which were labelled with a reporter molecule and an antibody 
specific for the marker. SERS was critical for the detection of disease, especially as the authors noted 
that conventional immunoassay formats had failed to detect the protein in human sera. [84] In an 
extension of this initial work Porter et al. developed an immunoassay system which could 
simultaneously detect two markers of pancreatic cancer. [85] The detection of multiple disease 
markers is a key step in the future of disease diagnosis since it is rare for disease processes to be 
represented or characterised by a single indicator. [13] In addition, the detection of multiple aspects 
of a disease will undoubtedly lead to better personalised medicine and immunoassays could be 
extended to detect a plethora of diseases simultaneously.  
 
Cell based detection is a vast field and in particular research has centred on detecting breast cancer. 
[87, 88] One of the earliest studies employed SERS dots (a form of silica encapsulated nanotags) 
functionalised with breast cancer (HER2) or leukaemia specific antibodies (CD10). [87] Antibody 
functionalisation was required so that the dots would bind specifically to the corresponding cell line 
and when the conjugates were incubated with different cell populations this specificity was 
observed. [87] HER2-functionalised dots only bound to the breast cancer cells and similarly the CD10 
functionalised dots bound only to the leukaemia cells. [87] SERS signals were not observed when 
either of the antibody functionalised nanotags was incubated with the control cell population. [87] 
This initial study highlighted the possibility of screening cell populations for cancerous and non-
cancerous cells and, provided that each subset of dots was labelled with a distinct reporter and an 
antibody, a range of disease could be detected simultaneously. The authors also reported that the 
method could potentially be implemented as an alternative to the radioactive tagging of cells and 
tissues. [87] 
 
Later, studies took advantage of the same binding relationship between HER2 antibodies and the 
corresponding receptors on cell membranes. [89, 90] However, rather than focusing on spherical 
shaped nanostructures rods and HGNs were investigated as alternative imaging scaffolds. [89, 90] In 
both instances, recognition via the specific antibody-antigen interaction was achieved and brighter 
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images were observed (Figure 2). [89, 90] The increased SERS intensity in the false colour images 
were not the result of any improvement in the binding efficiency but were a direct result of the 
enhanced optical properties demonstrated by both the rods and HGNs (Figure 2). [89, 90] The 
authors suggested that both systems are extremely sensitive imaging agents and when designing a 
disease detection system consideration should also be given to the imaging scaffold especially if the 
disease target is present at low concentrations. [89, 90]  
 
 
Figure 2 : Left panel  ? differential levels of binding between a) gold nanospheres and b) rods functionalised 
with HER2 antibody and exposed to MCF7 cells overexpressing HER2. [90] Modified and reproduced from [90] 
with permission from the PCCP owner societies. Right panel  ? differential levels of binding between a) HGNs 
and b) silver nanoparticles functionalised with HER2 antibody and exposed to MCF7 cells overexpressing HER2, 
c) intensity ratios for the peaks at I1620/I1371 for the crystal violet reporter.[89] Reprinted with permission from 
Elsevier. 
 
In a recent study antibody-antigen interactions were studied as means for differentiating between 
disease states. [72] The development of the nanostructures involved the labelling of silver 
nanoparticles with reporter molecules, and HER2 antibodies were subsequently conjugated via the 
terminal carboxylic acid group on the reporter. [72] The functionalised nanostructures were then 
exposed to two cell lines (SKBR3 and MCF7) which demonstrated a differential level of HER2 
expression. [72] In the SKBR3 cell line which exhibits a high level of HER2 expression the SERS signal 
was observed by the authors to be 3-4 times greater than in MCF7 cells, which have a low level of 
expression. [72] Although significantly greater levels of data would need to be collected from cells, 
at a number of different disease stages, this preliminary study highlights the implementation of SERS 
nanotags for the categorisation of cancerous disease states. The principles of the study are not 
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limited to cancer and any other condition which exhibits differential levels in the expression of 
disease markers could be analysed and graded in an analogous manner.  
 
In the most recent study, implementing breast cancer cell lines, the cell phenotype was determined 
from specific antibody antigen interactions occurring between nanostructures labelled with 
antibodies and antigen receptors present on cell surfaces. [91] This was achievable because each of 
the nanostructures was labelled with a different reporter molecule and thus different SERS signals 
were measured (Figure 3). [91] The false colour SERS maps were subsequently used as a method to 
quantify the level of biomarker expression since the SERS intensity is a direct measure of the 
concentration of biomarker. [91]  
 
 
Figure 3: Silica encapsulated hollow gold nanoshells (SEHGNs) used to phenotypically identify cancerous cell 
lines and determine the level of antigen expression in each cell line  ? a) SEHGNs were applied to the different 
cell lines and each of the cell types were identified based on the signal from the specific reporter molecules 
and b) SERS mapping images of the corresponding cell lines were measured at 1650 cm
 1 
(RBITC), 1619 cm
-1
 
(MGITC) and 1490 cm
-1
 (RuITC) for the SK-BR-3, KPL4 and MDA-MB-468 cell line specific reporter molecules. 
[91] Modified and reprinted with permission from Elsevier. 
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Biomarker or protein expression can also be used to differentiate cancerous from non-cancerous 
cells. [92] In prostate cancer cells neuropilin-1 is overexpressed and, on the basis of this knowledge, 
selective SERS nanotags were constructed for differentiating between cell lines. [92] To actively 
target cancerous cells or more specifically the receptors, nanotags were functionalised with a 
peptide with a specific affinity for neuropilin. [92] Control nanotags were functionalised with the HIV 
transactivator of transcription (TAT) peptide sequence and these nanotags had the ability to bind to 
both cells lines. [92] In order to positively identify the cancerous cells, the ratio of the SERS signal 
from each of the reporters was calculated. [92] The cancerous cells should have a high contribution 
from the reporter on the specific targeting nanotags whilst the non-cancerous cells should have a 
high contribution from the reporter on the control system. [92] This was found to represent a viable 
method for differentiating between the two cell lines. [92] Prostate cancer cells can also be 
positively identified from interactions between imaging agents and surface carbohydrates. [93] For 
example, PC3 cancerous cells exhibit elevated levels of sialic residues on their surface. [93] These 
can be actively targeted with nanostructures functionlised with the lectin, Triticum vulgaris, which is 
known to have a specific affinity for these glycans. [93] Craig et al. demonstrated this lectin-glycan 
interaction and in doing so successfully distinguished cancerous PC3 cells from the non-cancerous 
PNT2A cells. [93] 
 
Further applications involving the detection of cancerous cells have centred on circulating tumour 
cells (CTCs). Unlike other applications, which might be concerned with the primary detection of 
cancer, CTCs are particularly aggressive and are associated with the initiation of further cancerous 
growth. [73, 94] During an initial study the CTCs were exposed to antibody functionalised nanotags 
and magnetic beads. The nanotags whilst simultaneously binding to the CTCs acted as the reporter 
component and similarly, the magnetic beads whilst capable of binding to the cancer cells were 
incorporated so that the samples could be concentrated via a magnet. [73] The implementation of 
this method has resulted in successful detection of CTCs via SERS. [73] Detection was also achievable 
with high sensitivity and specificity when whole blood was employed. [73] In a subsequent study by 
Wang et al. a similar method was employed but the incorporation of magnetic beads was 
substituted for a physical separation step. [94] Initially, the blood was separated by centrifugation 
and, because of their low density, CTCs were removed from the upper portion of the container with 
relative ease. [94] CTCs were then incubated with nanotags for a specified period and after this any 
unbound nanotags were also removed by centrifugation prior to the SERS analysis. [94] Both 
methods allow for sensitive and selective detection of CTCs. [73, 94] 
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In a final example of SERS based disease detection in vitro, targeting of stem cells was investigated. 
Although this is not strictly a method for the detection of disease, stem cells have an important role 
in disease research. [95] In this study nuclear targeting SERS nanotags were deployed to ascertain 
the differences between differentiated and undifferentiated stem cell populations. [95] The cells 
were analysed by SERS and spectral information was extracted. Principal component analysis (PCA) 
was employed and it revealed that there were distinct differences between the two stem cell forms 
with regards to the organisation of the nucleus. These changes were suitably distinct and allowed for 
cell identification. [95] 
 
3.2 SERS and Ex vivo/In vivo Applications for the Detection of Disease 
3.2.1 Tissue Imaging and Disease Detection 
The use of SERS for disease related tissue imaging was initially performed by Schlucker et al. in 2006. 
[96] The SERS based detection system consisted of gold nanoparticles conjugated to an antibody via 
a small molecule reporter and this was used to actively detect prostate specific antigen (PSA) in 
tissue samples. [96] In a later study the same group extended this to monitor PSA expression in 
tissues. [80] This predominantly occurs in the epithelium of the prostate and, when incubated with 
functionalised nanoshells, the localised expression was confirmed by SERS signals arising from the 
specific nanoshell antibody-tissue antigen interaction and it was particularly evident in the false 
colour SERS maps (Figure 4). [80] Determining the localisation of other components within the tissues 
is not isolated to biomarkers of disease and the group successfully determined the localisation of the 
tumour suppressor p63, in non-cancerous tissue. [97] Elucidation of this was again determined by 
SERS signals arising from the specific interaction between the detection system and tissue. [97] 
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Figure 4: Detection of PSA ex vivo  ? top: bright field microscope image of a prostate tissue section. The grid 
shows the locations at which Raman spectra were acquired in a point mapping experiment. The false colour 
SERS image shows that the characteristic signal of the SERS-labelled antibody is observed selectively in the 
epithelium. Reproduced from [80] with permission from the PCCP Owner Societies.  
 
Whilst detection systems like this might seem trivial, they are actually of huge importance for the 
characterisation of disease in tissue. In all of the examples discussed, the measured signals arise 
from the SERS reporters. However, a second laser line could be employed at a frequency where the 
nanotags are not SERS active but where intrinsic Raman signals from the tissues dominate. This 
would allow biochemically characteristic information to be obtained from the tissues and the false 
colour SERS images could be used to delineate the boundaries between the regions where, for 
example, PSA expression is high and low. This would provide further information which is 
biochemically representative of the disease biomarkers. Whilst areas of protein expression can be 
imaged using traditional immunohistochemical methods, no biochemical information is obtained. 
Additionally, conventional fluorophores have broad absorption and emission bands so the staining of 
multiple areas is difficult. However, when employing either Raman and/or SERS imaging, the spectral 
bands are narrow and not limited in the tissue regions or receptors which could be targeted 
simultaneously. This is particularly important as the documentation of disease processes progresses 
towards the detection of multiple markers. [13]  
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Manipulation of the antibody-antigen interaction has also been exploited for the determination of 
nasopharyngeal cancer in tissue samples. [98] As with most of the discussed samples, antibody 
functionalised SERS nanotags were exposed to tissues. [98] Clinical samples were analysed and 
directly compared with the tissue, which had been analysed via a traditional immunohistochemical 
method. SERS analysis was found to considerably exceed the conventional method. [98] In total, 
there were 34 cancerous and 20 non-cancerous tissue samples and the SERS detection method 
correctly identified 33 of the cancerous samples whilst the traditional method only identified 22. 
[98] Negative samples were correctly identified by both methods. [98] As with the previous 
examples all of the above discussed advantages of the SERS method are equally applicable to this 
study. [98] 
 
SORS has been previously discussed as a method for disease detection in section 2.2. SORS has also 
been developed to incorporate a surface enhanced method known as surface enhanced spatially 
offset Raman spectroscopy (SESORS). [99] The key feature and main advantage of this technique is 
that it can measure Raman or SERS signals through medically relevant tissue depths. [99] This is of 
huge importance since it actively demonstrates non-invasive detection of disease. [99] In one of the 
latest studies cumulative SERS signals were measured from four different SERS nanotags which were 
located within tissue at a depth of 20 mm. [99] Even more significantly, it was possible to measure 
SERS signals through 50 mm of tissue. [99] This study highlights the possibility of implementing SERS 
and their nanotags for use in vivo.  
 
In a subsequent study the method was investigated in specific relation to a disease process. [100] 
Osteoporosis is a progressive bone disease which can be treated with drugs known as 
bisphosphonates. [100] The disease itself was not investigated but rather the study was designed to 
replicate drug distribution and investigate its localisation. [100] In order to do this, the drug was 
conjugated to SERS nanotags and subsequently incubated with representative bone samples. The 
bones were then transplanted into a tissue mass and the samples were analysed. [100] It was 
possible to detect the drug-nanotag conjugates at a depth of 20 mm. [100] Although this study did 
not involve the direct detection of the disease it is nonetheless important because it actively 
demonstrates the ability to monitor drug distribution non-invasively. [100] This therefore highlights 
the suitability of SERS as a key process in the treatment of disease.   
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3.2.2 In vivo Imaging and Disease Detection 
One of the most recognisable and well documented examples of in vivo SERS imaging is undoubtedly 
the study by Qian et al., [101] where tumours were successfully targeted with an antibody 
functionalised gold nanoparticle system in vivo. [101] The nanotag conjugates were introduced into 
the mice model via tail injection and they were successfully translocated to tumour locations. [101] 
Successful targeting was demonstrated via monitoring of the SERS signals and those measured from 
the tumour regions of the mouse were found to be representative of the reporter from the SERS 
nanotags (Figure 5). [101] This study actively demonstrated that the nanoparticles were able to 
travel through the animal model and reach their targets. [101] It was also critical for demonstrating 
the success and application of SERS for monitoring such interactions in vivo. 
 
 
Figure 5: In vivo cancer targeting and surface enhanced Raman detection by using ScFv-antibody conjugated 
gold nanoparticles that recognise the tumour biomarker EGFR. (a,b) SERS spectra obtained from the tumour 
and the liver locations by using targeted (a) and nontargeted (b) nanoparticles. Two nude mice bearing human 
head-and-neck squamous cell carcinoma (Tu686) xenograft tumour (3-mm diameter) received 90 µL of ScFv 
EGFR-ĐŽŶũƵŐĂƚĞĚ ^Z^ ƚĂŐƐ Žƌ ƉĞŐǇůĂƚĞĚ ^Z^ ƚĂŐƐ  ? ? ? ? ʌD ) ? dŚĞƉĂƌƚŝĐůĞƐ were administered via tail vein 
single injection. SERS spectra were taken 5 h after injection. (c) Photographs showing a laser beam focusing on 
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the tumour site or on the anatomical location of liver. In vivo SERS spectra were obtained from the tumour site 
(red) and the liver site (blue) with 2-s signal integration and at 785 nm excitation. The spectra were 
background subtracted and shifted for better visualisation. The Raman reporter molecule is malachite green, 
with distinct spectral signatures as labelled in a and b. Laser power, 20 mW. Reprinted by permission from 
Macmillan Publishers Ltd. Nature Biotechnology, [101] (2008). 
 
In vivo imaging of SERS nanotags has also been applied for the observation of inflammation and 
again, while not a disease process, it is of relevance since any change can be indicative of infection 
and underlying disease conditions. [102] Nanotags were functionalised with antibodies which have a 
specific affinity for the identified inflammation biomarker, intracellular adhesion molecule 1  ? 
(ICAM-1-). The nanotags specifically targeted inflammation in vitro, ex vivo and in vivo. [102] When 
the effectiveness of the SERS approach was directly compared with the conventional fluorescence 
method it was found to be significantly more sensitive. [102]  
 
Whilst the previous examples have demonstrated active in vivo disease targeting, a multi marker 
approach is considered to be beneficial, especially if multiple disease aspects are to be detected 
simultaneously. [13] It is hoped that by analysing disease processes or even multiple different 
diseases it will lead to better characterisation and personalised medicine.  
 
With the advent of superior nanotag systems, which display excellent stability and are optically  ‘hot ?, 
the possibility of multiplexed imaging in vivo has become a real possibility. [13, 76] In the initial 
stages it was possible to simultaneously detect two different nanotags within a live subject but this 
was latterly extended to include the simultaneous detection of ten different nanotags (Figure 6). [13, 
76] This was a crucial step forward for multiplexed detection in vivo, actively demonstrating the 
potential to detect multiple pathosis or different elements of disease simultaneously. [13] In a 
further extension of the work, in terms of true multiplexing and the confident identification of 
nanotags present within a specified location, it was possible to positively identify four nanotags in a 
multiplexed scenario. [13]  
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Figure 6: Evaluation of multiplexing 10 different SERS nanoparticles in vivo. Raman map of 10 different SERS 
particles injected subcutaneously in a nude mouse. Grayscale bar to the right depicts the Raman intensity, 
where white represents the maximum intensity and black represents no intensity. [13] C.L. Zavaleta, B.R. 
Smith, I. Walton, W. Doering, G. Davis, B. Shojaei, M.J. Natan, S.S. Gambhir, Proc. Natl. Acad. Sci. USA., 106  
(2009), 13511-13516. Copyright (2009) National Academy of Sciences of the United States of America.  
 
Further in vivo applications have been demonstrated by Maiti et al.[103-105] In the first of their in 
vivo experiments nanotags were injected into a mouse model and successfully imaged using 
SERS.[103] The only difference being that the antibody functionalised nanotags were actively bound 
to cancerous cells prior to their introduction, highlighting the opportunity to successfully image the 
nanotags in vivo even after participation in a disease recognition event. [103] In an extension to this 
work nanotags functionalised with antibodies which had a specific affinity for the receptors in the 
xenograft were found to translocate to the xenograft site following introduction into the animal. 
[104] Thus the conjugates participated in antibody-antigen recognition and signals representative of 
the reporter molecule were measured at the xenograft site. [104] However, when nanotags were 
introduced into mice bearing xenografts of the non-cancerous cell population SERS signals were not 
measured in accordance with the absence of a specific binding event. [104] 
 
In the most recent of their work, the group elegantly demonstrated the selectivity of their targeting 
nanotags. [105] In this study the xenograft was composed of oral squamous cell carcinoma (OSCC) 
cells which exhibit a differential level of expression of EGFR and HER2. EGFR receptors are present at 
a much higher level than HER2 receptors on the surface of the OSCC cells. [105] In accordance with 
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the expressed receptors three nanotags were injected into the tail of the animal subject, two of 
which had been functionalised with the EGFR specific antibody and the remaining nanotag was 
functionalised with the HER2 antibody. [105] The signals which were measured from the site of the 
xenograft were in accordance with the two nanotags functionalised with the specific antibody and 
two different reporter molecules. There was no contribution from the nanotag functionalised with 
the HER2 antibody (Figure 7). This study represents one of the first true targeted in vivo multiplexing 
examples and this is an important step forwards in terms of striving towards the deliverable of 
comprehensively characterising and detecting multiple aspects of disease. [105]  
 
 
Figure 7: In vivo multiplex detection in xenograft tumour  ? a) Normalised SERS spectra of CyNAMLA-381, 
Cy7LA and Cy7.5LA after chemisorption of AuNPs and b)  ? A: SERS spectra from tumour site (peaks obtained at 
503 and 586 cm
-1
 from two EGFR positive nanotags, Cy7LA and Cy7.5LA), B: SERS spectra from liver site (peaks 
obtained at 503, 523 and 586 cm
-1
) from two EGFR nanotag Cy7LA, Cy7.5 and anti-HER2 nanotag CyNAMLA-
381) and C: SERS spectra from dorsal region. [105] Modified and reprinted with permission from Elsevier. 
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4. SERS as a Method for Disease Treatment 
The idea of implementing nanoscaffolds for disease treatment is not a new concept and 
nanostructures in many different forms (i.e. nanorods, nanoshells and nanoparticles), predominantly 
gold based, have been utilised for the destruction of cancerous cells. [53, 106-111] This occurs 
because nanostructures absorbing the interrogating laser light results in localised heating, which is 
subsequently dissipated to the cell resulting in destruction. [53, 106, 107, 112, 113] It is widely 
believed that an increase in temperature is responsible for this effect but recent studies have shown 
that cellular damage can result without a significant temperature increase. [114] The method must 
therefore elicit some of form of damage which can ultimately result in cell death. [114, 115] While 
there are many examples highlighting the use of nanomaterials for therapeutic purposes, there are 
no demonstrated applications where SERS has been employed as a treatment method. However, its 
use has recently been critical in determining the localisation of nanostructures so that treatment can 
be targeted to a specific position. SERS is therefore becoming a key step in treatment processes.  
 
The detection of bacteria which are drug resistant is one such field where this method might be 
beneficial. Fan et al. described the generation of popcorn shaped magnetic nanoparticles which 
consisted of an iron core and a gold shell. [116] The nanostructures were further labelled with an 
antibody with affinity for Salmonella DT104. [116] In the study the nanoparticles were found to bind 
to the Salmonella cells with high affinity and, because of their magnetic properties, cells could be 
extracted from the bulk solution. [116] Cells were then destroyed by illuminating with a therapeutic 
light source. [116] As with several of the studies which will be discussed, SERS was not directly 
involved in the treatment process, but it was essential for determining that the nanoparticle 
conjugates had successfully bound to the target cells and without these conjugates treatment would 
not have been successful. [116] While this remains a preliminary study the method is postulated as 
an alternative to drug based treatment methods for bacterial infections and disease, and this has 
important consequences since drug resistance continues to increase. [116] 
 
Implementation in the detection of lung cancer is another field where these SERS based detection 
methods might be beneficial, especially since lung cancer is often diagnosed beyond a stage of 
effective treatment. [113] In a study by Wu et al. aptamer conjugated silver shell gold core 
nanoparticles labelled with rhodamine 6G were used for the specific targeting of A549 lung cancer 
cells. The specificity of the system was tested against six cell lines (two generic cancer and four lung 
cancer cell lines) and the aptamer conjugates were not found to give a significant SERS response, 
suggesting that the conjugates did not bind to any other cell lines except those which were 
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specifically targeted. [113] Implementation of the aptamer system allowed for considerable levels of 
aggregation between the cancer cells to occur since aptamers on a single shell could bind to 
different cells within the exposed population. [113] This was beneficial since it created concentrated 
areas of the conjugates and cells, ideal preparation for SERS detection and treatment with the 
irradiating laser. During the study it was found that a laser power of 0.2 W cm
-1 
applied for 60 min 
was sufficient to kill the cancerous cells. [113] The SERS response was also observed to decline 
following application of the treatment laser and it was postulated that this could be used as a 
measure of treatment efficacy. [113] When the same procedure was performed with the conjugates 
and the remaining cell lines, cell damage or death was not observed. The authors highlighted that 
this method could be applied for the medical treatment of cancer since differentiation between the 
cancerous cells was both selective and specific. [113] In this particular application SERS has been 
implemented to confirm the binding reaction and the possibility exists for it to be used as an 
indicator of treatment progression. Although not directly responsible for the treatment the 
implementation of SERS was critical to the overall therapeutic procedure and success of the system. 
 
Such procedures are not isolated to the treatment of lung cancer and a similar scenario was 
developed for breast cancer cells (BT-549). [117] In this procedure gold nanostars which had been 
previously pegylated were ůĂďĞůůĞĚ ǁŝƚŚ ƚŚĞ ƌĞƉŽƌƚĞƌ ŵŽůĞĐƵůĞ  ? ?  ? ?-diethylthiadicarbocyanine 
(DTDC) before silica encapsulation and further labelling with the phototherapeutic drug 
protoporphyrin IX (PpIX) and the cell penetrating peptide TAT. [117] In the study SERS was employed 
to monitor the uptake of the nanostars by breast cancer cells. When functionalised with the TAT 
peptide considerable SERS signals were observed. However, when the peptide sequence was 
removed from the conjugate, SERS signals were significantly reduced or not detected. [117] This is 
consistent with observations that functionalisation with the TAT peptide aids in the cellular uptake 
of nanomaterials. [117-119] In this particular study, TAT functionalisation was critical for the 
successful treatment of cancerous cells using PpIX. PpIX is used as an initiator for the production of 
damaging oxygen species which in turn continues the cascade of reactions initiating cellular damage 
and death. [117] Following exposure to the therapeutic light source, cell death was apparent in 
those cells which had been subject to the TAT functionalised conjugates whilst no significant effect 
was observed in those exposed to the TAT or PpIX free nanostructures (Figure 8). [117] The use of 
SERS in this study was again critical for determining the successful targeting of the conjugates, and 
whilst it is not directly responsible for the therapeutic effects observed, without it the delivery of the 
treatment could not be confirmed. [117] 
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Figure 8: Viability staining of cells incubated with AuNS-DTDC@SiO2-PpIX-TAT (left) and AuNS-DTDC@SiO2-TAT 
(right) after 30 s of light irradiation. Live cells are stained green and dead cells are stained red. Scale bars are 
250 µm. Reprinted with permission from [117]. Copyright (2013) American Chemical Society. 
 
In a further example silver nanotriangles encapsulated in chitosan and labelled with a reporter 
molecule and folic acid were used for the treatment of ovarian cancer cells (NIH-OVCAR-3). [120] 
Folic acid was essential for transporting the conjugates across the cell membrane via a receptor 
mediated targeting strategy. [120] SERS was again implemented to confirm the transport of the 
nanostructures to their specified targets. Treatment with the therapeutic laser lead to cell death and 
the levels of cellular destruction were correlated with nanostructure concentration. [120] This 
method could be used to deliver therapeutics specifically to a diseased cell population since 
nanotriangle uptake between the cancerous and non-cancerous cells should vary in accordance with 
the expression of cancer related receptors. [120] SERS was again a vital step in the overall treatment 
process.  
 
While cell based examples are undoubtedly interesting and stimulate further research this ultimately 
must be translated to in vivo applications. Conde et al. developed gold nanoparticle conjugates 
which were labelled with a reporter molecule and the antibody-drug conjugate Cetuximab (Erbitux®) 
for targeted detection and treatment of tumours in vivo. [121] Mice models were implanted with 
cancerous cells to generate xenografts [121] and mice were then treated with nanostructures via tail 
injection, while the tumours were located in the right leg. [121] The conjugates were successfully 
translocated to the tumour site and resulted in a reduction of further tumour development by the 
inhibition of cellular division. [121] Active targeting of the tumour was monitored via SERS and large 
SERS signals were observed in mice treated with the drug conjugates whilst minimal signals were 
observed from those treated with drug-free nanostructures (Figure 9). [121] The authors reported 
that the signals measured from drug labelled nanoparticles at the xenograft were 4.5 times higher 
than those of the drug free system as measured from a key identification peak at 508 cm
-1
. [121] The 
variation in the SERS signal between the two sites and samples presumably arises because the drug-
free conjugates are not specifically targeting the tumour site. [121] The SERS studies were 
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performed ex vivo but the method further highlights the implementation of SERS based conjugates 
and SERS as a method for the successful targeting and treatment of disease in vivo. [121] 
 
 
Figure 9: Drug ?Raman NP uptake and bio-distribution in whole body mice. Representative imaging of 
individual mice from each group (n = 10 animals) is shown, with the same scale of epi-fluorescence (a,b) 
indicating emission signal from the Raman reporter, DTTC (Emission = 780 ?800 nm). (c) Evaluation of 
nanoparticles distribution in mice organs treated with Raman- and drug ?Raman NPs. (d) SERS spectra of the 
tumour site, measured through the tumour tissues excised from the mice, of drug-Raman NPs (blue line), 
Raman NPs only (black line) and other anatomical locations (i.e., the opposite leg, red line). Characteristic SERS 
peak at 508 cm
A?1
. [121] Reprinted with permission from Elsevier. 
 
5. Conclusion 
The rich and varied applications of Raman and more significantly SERS for the detection of diseases 
are direct consequences of the numerous advantages that they confer. Unlike their fluorescent 
counterparts, sharp molecularly specific spectra are obtained, which instantly and readily lends the 
techniques to multiplexed disease detection opportunities. As demonstrated in some of the 
examples discussed, detection via these methods is often more sensitive and selective. In addition, 
the possibility exists for combined Raman and SERS imaging of cells and tissues so that in the advent 
of implementing SERS active nanotags, biochemical and characteristic information relating to the 
disease process can be simultaneously obtained. In order for SERS to achieve and remain at the 
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forefront of disease diagnostics further studies are required in physiological representative media, 
clinical samples and in vivo. When these applications fully demonstrate their robustness, reliability, 
repeatability, sensitivity and selectivity in vivo, the technique will make the full transition from the 
laboratory to a clinical setting. Presently, the techniques are strong contenders for revolutionising 
our ability to detect disease. 
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